|
1
|
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global cancer statistics 2020:
GLOBOCAN estimates of incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin. 71:209–249. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Denisenko TV, Budkevich IN and Zhivotovsky
B: Cell death-based treatment of lung adenocarcinoma. Cell Death
Dis. 9:1172018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Reck M and Rabe KF: Precision diagnosis
and treatment for advanced non-small-cell lung cancer. N Engl J
Med. 377:849–861. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Li Y, Yan B and He S: Advances and
challenges in the treatment of lung cancer. Biomed Pharmacother.
169:1158912023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Obradovic J, Todosijevic J and Jurisic V:
Application of the conventional and novel methods in testing EGFR
variants for NSCLC patients in the last 10 years through different
regions: A systematic review. Mol Biol Rep. 48:3593–3604. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Jurisic V, Vukovic V, Obradovic J,
Gulyaeva LF, Kushlinskii NE and Djordjevic N: EGFR polymorphism and
survival of NSCLC patients treated with TKIs: A systematic review
and meta-analysis. J Oncol. 2020:19732412020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Obradovic J, Todosijevic J and Jurisic V:
Side effects of tyrosine kinase inhibitors therapy in patients with
non-small cell lung cancer and associations with EGFR
polymorphisms: A systematic review and meta-analysis. Oncol Lett.
25:622023. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Xu K, Ma J, Hall SRR, Pengs RW, Yang H and
Yao F: Battles against aberrant KEAP1-NRF2 signaling in lung
cancer: Intertwined metabolic and immune networks. Theranostics.
13:704–723. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ghareghomi S, Moosavi-Movahedi F, Saso L,
Habibi-Rezaei M, Khatibi A, Hong J and Moosavi-Movahedi AA:
Modulation of Nrf2/HO-1 by natural compounds in lung cancer.
Antioxidants (Basel). 12:7352023. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Imielinski M, Berger AH, Hammerman PS,
Hernandez B, Pugh TJ, Hodis E, Cho J, Suh J, Capelletti M,
Sivachenko A, et al: Mapping the hallmarks of lung adenocarcinoma
with massively parallel sequencing. Cell. 150:1107–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romero R, Sanchez-Rivera FJ, Westcott PMK,
Mercer KL, Bhutkar A, Muir A, Robles TJ, Rodriguez SL, Liao LZ, Ng
SR, et al: Keap1 mutation renders lung adenocarcinomas dependent on
Slc33a1. Nat Cancer. 1:589–602. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Romero R, Sayin VI, Davidson SM, Bauer MR,
Singh SX, LeBoeuf SE, Karakousi TR, Ellis DC, Bhutkar A,
Sanchez-Rivera FJ, et al: Keap1 loss promotes Kras-driven lung
cancer and results in dependence on glutaminolysis. Nat Med.
23:1362–1368. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zavitsanou AM, Pillai R, Hao Y, Wu WL,
Bartnicki E, Karakousi T, Rajalingam S, Herrera A, Karatza A,
Rashidfarrokhi A, et al: KEAP1 mutation in lung adenocarcinoma
promotes immune evasion and immunotherapy resistance. Cell Rep.
42:1132952023. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ghareghomi S, Habibi-Rezaei M, Arese M,
Saso L and Moosavi-Movahedi AA: Nrf2 modulation in breast cancer.
Biomedicines. 10:26682022. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Menegon S, Columbano A and Giordano S: The
dual roles of NRF2 in cancer. Trends Mol Med. 22:578–593. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kerins MJ and Ooi A: A catalogue of
somatic NRF2 gain-of-function mutations in cancer. Sci Rep.
8:128462018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li C, Liang G, Yan K and Wang Y: NRF2
mutation enhances the immune escape of hepatocellular carcinoma by
reducing STING activation. Biochem Biophys Res Commun.
698:1495362024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tang H, Liu S, Yan X, Jin Y, He X, Huang
H, Liu L, Hu W and Wu A: Inhibition of LNC EBLN3P enhances
radiation-induced mitochondrial damage in lung cancer cells by
targeting the Keap1/Nrf2/HO-1 axis. Biology (Basel).
12:12082023.PubMed/NCBI
|
|
19
|
Spampinato M, Sferrazzo G, Pittala V, Di
Rosa M, Vanella L, Salerno L, Sorrenti V, Carota G, Parrinello N,
Raffaele M, et al: Non-competitive heme oxygenase-1 activity
inhibitor reduces non-small cell lung cancer glutathione content
and regulates cell proliferation. Mol Biol Rep. 47:1949–1964. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Director's Challenge Consortium for the
Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor
JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL, Eschrich S,
Jurisica I, Giordano TJ, et al: Gene expression-based survival
prediction in lung adenocarcinoma: A multi-site, blinded validation
study. Nat Med. 14:822–827. 2008. View
Article : Google Scholar
|
|
21
|
Lanczky A and Gyorffy B: Web-based
survival analysis tool tailored for medical research (KMplot):
Development and implementation. J Med Internet Res. 23:e276332021.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ritchie ME, Phipson B, Wu D, Hu Y, Law CW,
Shi W and Smyth GK: limma powers differential expression analyses
for RNA-sequencing and microarray studies. Nucleic Acids Res.
43:e472015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Liu Z, Liu L, Weng S, Guo C, Dang Q, Xu H,
Wang L, Lu T, Zhang Y, Sun Z and Han X: Machine learning-based
integration develops an immune-derived lncRNA signature for
improving outcomes in colorectal cancer. Nat Commun. 13:8162022.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Miao YR, Zhang Q, Lei Q, Luo M, Xie GY,
Wang H and Guo AY: ImmuCellAI: A unique method for comprehensive
T-cell subsets abundance prediction and its application in cancer
immunotherapy. Adv Sci (Weinh). 7:19028802020. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maeser D, Gruener RF and Huang RS:
oncoPredict: An R package for predicting in vivo or cancer patient
drug response and biomarkers from cell line screening data. Brief
Bioinform. 22:bbab2602021. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Detterbeck FC, Woodard GA, Bader AS, Dacic
S, Grant MJ, Park HS and Tanoue LT: The proposed ninth edition TNM
classification of lung cancer. Chest. 166:882–895. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lou JS, Zhao LP, Huang ZH, Chen XY, Xu JT,
Tai WC, Tsim KWK, Chen YT and Xie T: Ginkgetin derived from Ginkgo
biloba leaves enhances the therapeutic effect of cisplatin via
ferroptosis-mediated disruption of the Nrf2/HO-1 axis in EGFR
wild-type non-small-cell lung cancer. Phytomedicine. 80:1533702021.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Bi G, Liang J, Zhao M, Zhang H, Jin X, Lu
T, Zheng Y, Bian Y, Chen Z, Huang Y, et al: miR-6077 promotes
cisplatin/pemetrexed resistance in lung adenocarcinoma via
CDKN1A/cell cycle arrest and KEAP1/ferroptosis pathways. Mol Ther
Nucleic Acids. 28:366–386. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mei L, Long J, Wu S, Mei M, Mei D and Qiu
H: APOC1 reduced anti-PD-1 immunotherapy of nonsmall cell lung
cancer via the transformation of M2 into M1 macrophages by
ferroptosis by NRF2/HO-1. Anticancer Drugs. 35:333–343. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wei XW, Lu C, Zhang YC, Fan X, Xu CR, Chen
ZH, Wang F, Yang XR, Deng JY, Yang M, et al: Redox(high) phenotype
mediated by KEAP1/STK11/SMARCA4/NRF2 mutations diminishes
tissue-resident memory CD8+ T cells and attenuates the efficacy of
immunotherapy in lung adenocarcinoma. Oncoimmunology.
13:23401542024. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fahrmann JF, Tanaka I, Irajizad E, Mao X,
Dennison JB, Murage E, Casabar J, Mayo J, Peng Q, Celiktas M, et
al: Mutational activation of the NRF2 pathway upregulates
kynureninase resulting in tumor immunosuppression and poor outcome
in lung adenocarcinoma. Cancers (Basel). 14:25432022. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Phillips RS: Structure and mechanism of
kynureninase. Arch Biochem Biophys. 544:69–74. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Karayama M, Masuda J, Mori K, Yasui H,
Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y,
et al: Comprehensive assessment of multiple tryptophan metabolites
as potential biomarkers for immune checkpoint inhibitors in
patients with non-small cell lung cancer. Clin Transl Oncol.
23:418–423. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Leon-Letelier RA, Sater AH, Chen Y,
Srejbhjv S, et al: Kynureninase upregulation is a prominent feature
of NFR2-activated cancers and is associated with tumor
immunosuppression and poor prognosis. Cancers (Basel). 15:8342023.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Liu BX, Xie Y, Zhang J, Zeng S, Li J, Tao
Q, Yang J, Chen Y and Zeng C: SERPINB5 promotes colorectal cancer
invasion and migration by promoting EMT and angiogenesis via the
TNF-α/NF-κB pathway. Int Immunopharmacol. 131:1117592024.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rathod M, Franz H, Beyersdorfer V, Wanuske
MT, Leal-Fischer K, Hanns P, Stüdle C, Zimmermann A, Buczak K,
Schinner C and Spindler V: DPM1 modulates desmosomal adhesion and
epidermal differentiation through SERPINB5. J Cell Biol.
223:e2023050062024. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
He X, Ma Y, Huang Z, Wang G, Wang W, Zhang
R, Guo G, Zhang X, Wen Y and Zhang L: SERPINB5 is a prognostic
biomarker and promotes proliferation, metastasis and
epithelial-mesenchymal transition (EMT) in lung adenocarcinoma.
Thorac Cancer. 14:2275–2287. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Scopetti D, Piobbico D, Brunacci C,
Pieroni S, Bellezza G, Castelli M, Ludovini V, Tofanetti FR, Cagini
L, Sidoni A, et al: INSL4 as prognostic marker for proliferation
and invasiveness in non-small-cell lung cancer. J Cancer.
12:3781–3795. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yang R, Li SW, Chen Z, Zhou X, Ni W, Fu
DA, Lu J, Kaye FJ and Wu L: Role of INSL4 signaling in sustaining
the growth and viability of LKB1-inactivated lung cancer. J Natl
Cancer Inst. 111:664–674. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bhattacharya D, Gawali VS, Kallay L,
Toukam DK, Koehler A, Stambrook P, Krummel DP and Sengupta S:
Therapeutically leveraging GABA(A) receptors in cancer. Exp Biol
Med (Maywood). 246:2128–2135. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Liu L, Yang C, Shen J, Huang L, Lin W,
Tang H, Liang W, Shao W, Zhang H and He J: GABRA3 promotes
lymphatic metastasis in lung adenocarcinoma by mediating
upregulation of matrix metalloproteinases. Oncotarget.
7:32341–32350. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Hanahan D and Coussens LM: Accessories to
the crime: Functions of cells recruited to the tumor
microenvironment. Cancer Cell. 21:309–322. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Binnewies M, Roberts EW, Kersten K, Chan
V, Fearon DF, Merad M, Coussens LM, Gabrilovich DI,
Ostrand-Rosenberg S, Hedrick CC, et al: Understanding the tumor
immune microenvironment (TIME) for effective therapy. Nat Med.
24:541–550. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Genova C, Dellepiane C, Carrega P,
Sommariva S, Ferlazzo G, Pronzato P, Gangemi R, Filaci G, Coco S
and Croce M: Therapeutic implications of tumor microenvironment in
lung cancer: Focus on immune checkpoint blockade. Front Immunol.
12:7994552021. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Song P, Li W, Guo L, Ying J, Gao S and He
J: Identification and validation of a novel signature based on NK
cell marker genes to predict prognosis and immunotherapy response
in lung adenocarcinoma by integrated analysis of single-cell and
bulk RNA-sequencing. Front Immunol. 13:8507452022. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Terabe M and Berzofsky JA: Tissue-specific
roles of NKT cells in tumor immunity. Front Immunol. 9:18382018.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Rad SH, Monkman J, Warkiani ME, Ladwa R,
O'Byrne K, Rezaei N and Kulasinghe A: Understanding the tumor
microenvironment for effective immunotherapy. Med Res Rev.
41:1474–1498. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ge Z, Peppelenbosch MP, Sprengers D and
Kwekkeboom J: TIGIT, the next step towards successful combination
immune checkpoint therapy in cancer. Front Immunol. 12:6998952021.
View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Acharya N, Sabatos-Peyton C and Anderson
AC: Tim-3 finds its place in the cancer immunotherapy landscape. J
Immunother Cancer. 8:e0009112020. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wojciechowicz K, Spodzieja M and Wardowska
A: The BTLA-HVEM complex-The future of cancer immunotherapy. Eur J
Med Chem. 268:1162312024. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Gebbia V, Lorusso V, Galetta D, Caruso MM,
Palomba G, Riccardi F, Borsellino N, Carrozza F, Leo S, Ferraù F,
et al: First-line cisplatin with docetaxel or vinorelbine in
patients with advanced non-small-cell lung cancer: A quality of
life directed phase II randomized trial of Gruppo Oncologico Italia
Meridionale. Lung Cancer. 69:218–224. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Fuentes-Baile M, Ventero MP, Encinar JA,
García-Morales P, Poveda-Deltell M, Pérez-Valenciano E, Barberá VM,
Gallego-Plazas J, Rodríguez-Lescure Á, Martín-Nieto J and Saceda M:
Differential effects of IGF-1r small molecule tyrosine kinase
inhibitors BMS-754807 and OSI-906 on human cancer cell lines.
Cancers (Basel). 12:37172020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Zhang C, Zhao X, Wang Z, Gong T, Zhao H,
Zhang D, Niu Y, Li X, Zhao X, Li G, et al: Dasatinib in combination
with BMS-754807 induce synergistic cytotoxicity in lung cancer
cells through inhibiting lung cancer cell growth, and inducing
autophagy as well as cell cycle arrest at the G1 phase. Invest New
Drugs. 41:438–452. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
DaCosta Byfield S, Major C, Laping NJ and
Roberts AB: SB-505124 is a selective inhibitor of transforming
growth factor-beta type I receptors ALK4, ALK5, and ALK7. Mol
Pharmacol. 65:744–752. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Wu TH, Chou YW, Chiu PH, Tang MJ, Hu CW
and Yeh ML: Validation of the effects of TGF-β1 on tumor recurrence
and prognosis through tumor retrieval and cell mechanical
properties. Cancer Cell Int. 14:202014. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Stathis A and Bertoni F: BET proteins as
targets for anticancer treatment. Cancer Discov. 8:24–36. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Wang J, Xu Y, Rao X, Zhang R, Tang J,
Zhang D, Jie X, Zhu K, Wang X, Xu Y, et al: BRD4-IRF1 axis
regulates chemoradiotherapy-induced PD-L1 expression and immune
evasion in non-small cell lung cancer. Clin Transl Med.
12:e7182022. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Mrdjanovic J, Solajic S, Srdenovic-Conic
B, Bogdanović V, Dea KJ, Kladar N and Jurišić V: The oxidative
stress parameters as useful tools in evaluating the DNA damage and
changes in the complete blood count in hospital workers exposed to
low doses of antineoplastic drugs and ionizing radiation. Int J
Environ Res Public Health. 18:84452021. View Article : Google Scholar : PubMed/NCBI
|
